Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, eslicarbazepine acetate (Zebinix®) cannot be endorsed for use within NHS Wales as monotherapy for the treatment of partial-onset seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy. |
||
|
||
Medicine details |
||
| Medicine name | eslicarbazepine acetate (Zebinix®) | |
| Formulation | 200 mg and 800 mg tablet | |
| Reference number | 1213 | |
| Indication | Monotherapy for the treatment of partial-onset seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy. |
|
| Company | Eisai Ltd | |
| BNF chapter | Central nervous system | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 07/08/2017 | |